Auditor Issues Going Concern Warning; Company Faces Nasdaq Delisting Risk and Regulatory Setbacks for Key Product

summarizeSummary

Cytosorbents Corp's annual report includes an auditor's going concern warning, details regulatory setbacks for its DrugSorb-ATR product, discloses new material weaknesses in financial controls, and confirms Nasdaq delisting risk, despite some revenue growth and cost-cutting measures.

check_boxKey Events

• Auditor Issues Going Concern Warning

  The independent registered public accounting firm has raised substantial doubt about the company's ability to continue as a going concern within the next twelve months, citing recurring losses, negative cash flows, and an accumulated deficit of $312.2 million as of December 31, 2025.

• Regulatory Setbacks for DrugSorb-ATR

  The FDA denied the De Novo request for DrugSorb-ATR in April 2025 and upheld the denial in August 2025, requiring a new application with additional real-world data. Health Canada also refused its Medical Device License application, delaying approval for the company's key product in North America.

• New Material Weakness in Internal Controls

  Management identified a new material weakness in financial statement consolidation and reporting for 2025, in addition to a continuing material weakness in accounting for stock-based compensation, indicating significant deficiencies in financial reporting processes.

• Nasdaq Delisting Risk

  The company is not in compliance with Nasdaq's minimum $1.00 bid price requirement and has filed for a 180-day extension, with a reverse stock split being considered if necessary to regain compliance.

auto_awesomeAnalysis

This annual report reveals critical challenges for Cytosorbents Corp, including an auditor's going concern warning, significant regulatory delays for its key DrugSorb-ATR product, and new material weaknesses in internal financial controls. The company's ability to continue operations is in substantial doubt, exacerbated by its non-compliance with Nasdaq's minimum bid price requirement. While the company has taken steps to reduce costs and secured some financing, the expiration of Series B warrants worthless and the contingency of future debt tranches on FDA approval highlight ongoing financial and operational pressures. Investors should be aware of the high risk of delisting and the uncertain path to market for its primary growth driver.